Fundraising Fox

Imara

NASDAQ: ELVN

Cambridge, US · Founded 2016 · Delaware corporation · 5 known investors

Biotech

Founders & leadership

JG
James G. McArthurExecutive
CM
Christoph M. AdamsExecutive

Board

SN
Sara NayeemBoard director
BD
Barbara DaltonBoard director
DM
David MottBoard director
RH
Robert HopfnerBoard director
MK
Mette Kirstine AggerBoard director

Investors · 5

Bay City CapitalSan Rafael · $5M – $10Mvia Carl Goldfischer · board
New Enterprise Associates (NEA)Menlo Park · $200K – $40M
RA CapitalBoston
Arix BiosciencereportedLondon
OrbiMedreported · 2 sourcesNew York · $1M – $75Mvia David Bonita · board

Reported raises · per SEC filings

Form D private placements

$140.1M disclosed across 3 rounds · 2016–2024

▶$90MraisedApr 2024 · 20 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Helen CollinsExecutive Officer
  • Andrew PhillipsDirector
  • Richard HeymanDirector
  • Mika DerynckDirector
  • Benjamin HohlExecutive Officer
  • Anish PatelExecutive Officer
  • Joseph P. LyssikatosExecutive Officer, Director
  • Jake BauerDirector
  • Rahul BallalDirector
  • Rishi GuptaDirector
  • Samuel KintzExecutive Officer, Director
Offering amount
$90M
Amount sold
$90M
First sale
Mar 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$44.1MraisedMar 2019 · 11 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • David BonitaDirector
  • Christoph M. AdamsExecutive Officer
  • Barbara DaltonDirector
  • James G. McArthurDirector
  • Rahul BallalExecutive Officer, Director
  • David MottDirector
  • Carl GoldfischerDirector
  • Mark ChinDirector
  • Mette Kirstine AggerDirector
  • Sara NayeemDirector
Offering amount
$63M
Amount sold
$44.1M
First sale
Mar 2019
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6MraisedApr 2016 · 7 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Sara NayeemDirector
  • Barbara DaltonDirector
  • David MottDirector
  • Robert HopfnerDirector
  • Mette Kirstine AggerDirector
  • James G. McArthurExecutive Officer, Director
  • Christoph M. AdamsExecutive Officer, Director
Offering amount
$31M
Amount sold
$6M
First sale
Apr 2016
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Trysignalbasetrysignalbase.com · Jul 2026After safety setbacks, job cuts, Imara sells its top drug to a startup | BioPharma Divebiopharmadive.com · Sep 2022Imara Raises $63 Million, Brings in Pfizer Rare Disease Head as CMO - Global Genesglobalgenes.org · Mar 2019Imara lands $63M crossover round to trial sickle cell drug | Fierce Biotechfiercebiotech.com · Mar 2019Imara closes $63M Series B funding round for blood disorder drug development - MedCity Newsmedcitynews.com · Mar 2019Imara Raises $31M in Series A Funding - FinSMEsfinsmes.com · Apr 2016

Frequently asked questions

Who are Imara's investors?
Imara's investors include Bay City Capital, New Enterprise Associates (NEA), RA Capital, Arix Bioscience, OrbiMed.
How much funding has Imara raised?
Imara has disclosed $140.1M raised across 3 rounds.
Where is Imara headquartered?
Imara is headquartered in Cambridge, US.